Demographic and clinical factors in the 92 participants reaching therapeutic dose
| Variable . | Value . |
|---|---|
| Age, mean (SD) | 58.2 (15.5) |
| BSA, m2, mean (SD) | 2 (0.3) |
| White, no. (%) | 79 (86) |
| African-American, no. (%) | 13 (14) |
| Female, no. (%) | 44 (48) |
| Therapeutic warfarin dose, geometric mean (SD) | 4.9 (2.5) |
| EBL, geometric mean (SD) | 376 (670) |
| INR0, geometric mean (SD) | 1.0 (0.1) |
| INR3, geometric mean (SD) | 1.6 (0.5) |
| Target INR, mean (SD) | 2.3 (0.2) |
| Warfarin dose, day before surgery, mean (SD) | 6.5 (2.3) |
| Warfarin dose, day of surgery, mean (SD) | 4.6 (1.7) |
| History of liver disease, no. (%) | 2 (2) |
| Smokes, no. (%) | 17 (18) |
| Takes amiodarone, no. (%) | 1 (1) |
| Takes simvastatin, no. (%) | 10 (11) |
| Takes fluvastatin, no. (%) | 7 (8) |
| Variable . | Value . |
|---|---|
| Age, mean (SD) | 58.2 (15.5) |
| BSA, m2, mean (SD) | 2 (0.3) |
| White, no. (%) | 79 (86) |
| African-American, no. (%) | 13 (14) |
| Female, no. (%) | 44 (48) |
| Therapeutic warfarin dose, geometric mean (SD) | 4.9 (2.5) |
| EBL, geometric mean (SD) | 376 (670) |
| INR0, geometric mean (SD) | 1.0 (0.1) |
| INR3, geometric mean (SD) | 1.6 (0.5) |
| Target INR, mean (SD) | 2.3 (0.2) |
| Warfarin dose, day before surgery, mean (SD) | 6.5 (2.3) |
| Warfarin dose, day of surgery, mean (SD) | 4.6 (1.7) |
| History of liver disease, no. (%) | 2 (2) |
| Smokes, no. (%) | 17 (18) |
| Takes amiodarone, no. (%) | 1 (1) |
| Takes simvastatin, no. (%) | 10 (11) |
| Takes fluvastatin, no. (%) | 7 (8) |
BSA indicates body surface area; EBL, estimated blood loss; INR0, international normalized ratio at baseline; and INR3, international normalized ratio after 3 warfarin doses.